Haven Capital Group Inc. Makes New $3.87 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Haven Capital Group Inc. purchased a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 52,279 shares of the medical research company's stock, valued at approximately $3,870,000. Edwards Lifesciences accounts for about 3.6% of Haven Capital Group Inc.'s investment portfolio, making the stock its 10th biggest position.

Other institutional investors have also bought and sold shares of the company. FSA Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences during the 3rd quarter valued at $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after acquiring an additional 308 shares during the period. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $46,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.7 %

Edwards Lifesciences stock traded down $0.50 during midday trading on Friday, reaching $70.46. The stock had a trading volume of 7,144,270 shares, compared to its average volume of 4,605,776. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a fifty day moving average of $71.48 and a 200 day moving average of $70.35. The firm has a market cap of $41.42 billion, a price-to-earnings ratio of 10.11, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of a number of recent analyst reports. Piper Sandler lifted their target price on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. Truist Financial reissued a "hold" rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and upped their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. This represents a 1.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 51,303 shares of company stock worth $3,715,776. Insiders own 1.29% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.